Pharmacists' naloxone services beyond community pharmacy settings: A systematic review
- PMID: 36156267
- DOI: 10.1016/j.sapharm.2022.09.002
Pharmacists' naloxone services beyond community pharmacy settings: A systematic review
Abstract
Background: Pharmacists' provision of naloxone services in community pharmacy settings is well-recognized. Recently, studies describing pharmacists' naloxone services in settings other than community pharmacies have emerged in the literature. There is a need to synthesize evidence from these studies to evaluate the scope and impact of pharmacists' naloxone services beyond community pharmacy settings.
Objectives: The objectives of this systematic review were to a) identify pharmacists' naloxone services and their outcomes, and b) examine knowledge, attitudes, and barriers (KAB) related to naloxone service provision in non-community pharmacy settings.
Methods: Eligible studies were identified using PubMed, Web of Science, and CINAHL. Inclusion criteria were as follows: peer-reviewed empirical research conducted in the U.S. from January 2010 through February 2022; published in English; and addressed a) pharmacists' naloxone services and/or b) KAB related to the implementation of naloxone services. PRISMA guidelines were used to report this study.
Results: Seventy-six studies were identified. The majority were non-randomized and observational; only two used a randomized controlled (RCT) design. Most studies were conducted in veterans affairs (30%) and academic medical centers (21%). Sample sizes ranged from n = 10 to 217,469, and the majority reported sample sizes <100. Pharmacists' naloxone services involved clinical staff education, utilization of screening tools to identify at-risk patients, naloxone prescribing and overdose education and naloxone dispensing (OEND). Outcomes of implementing naloxone services included improved naloxone knowledge, positive attitudes, increased OEND, and overdose reversals. Pharmacists cited inadequate training, time constraints, reimbursement issues, and stigma as barriers that hindered naloxone service implementation.
Conclusion: This systematic review found robust evidence regarding pharmacist-based naloxone services beyond community pharmacy settings. Future programs should use targeted approaches to help pharmacists overcome barriers and enhance naloxone services. Additional research is needed to evaluate pharmacist naloxone services by using rigorous methodologies (e.g., larger sample sizes, RCT designs).
Keywords: Attitudes; Barriers; Harm reduction; Knowledge; Naloxone; Pharmacists.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors report no conflict of interest.
Similar articles
-
Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.Ann Pharmacother. 2014 May;48(5):601-6. doi: 10.1177/1060028014523730. Epub 2014 Feb 12. Ann Pharmacother. 2014. PMID: 24523396 Free PMC article.
-
Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.Am J Health Syst Pharm. 2021 Feb 8;78(4):327-335. doi: 10.1093/ajhp/zxaa387. Am J Health Syst Pharm. 2021. PMID: 33336254
-
Evaluation of naloxone furnishing community pharmacies in San Francisco.J Am Pharm Assoc (2003). 2020 Nov-Dec;60(6):1050-1057.e1. doi: 10.1016/j.japh.2020.08.032. Epub 2020 Sep 15. J Am Pharm Assoc (2003). 2020. PMID: 32948461 Free PMC article.
-
Naloxone accessibility without an outside prescription from U.S. community pharmacies: A systematic review.J Am Pharm Assoc (2003). 2022 Nov-Dec;62(6):1725-1740. doi: 10.1016/j.japh.2022.07.008. Epub 2022 Jul 31. J Am Pharm Assoc (2003). 2022. PMID: 35989151 Review.
-
Pharmacist roles, training, and perceived barriers in naloxone dispensing: A systematic review.J Am Pharm Assoc (2003). 2020 Jan-Feb;60(1):178-194. doi: 10.1016/j.japh.2019.06.016. Epub 2019 Jul 29. J Am Pharm Assoc (2003). 2020. PMID: 31371179 Review.
Cited by
-
"I go out of my way to give them an extra smile now:" A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materials.Res Social Adm Pharm. 2024 May;20(5):512-519. doi: 10.1016/j.sapharm.2024.02.001. Epub 2024 Feb 10. Res Social Adm Pharm. 2024. PMID: 38395644
-
Effects of pharmacist-driven protocol on naloxone prescribing rates in two primary care clinics.Prev Med Rep. 2023 Nov 2;36:102493. doi: 10.1016/j.pmedr.2023.102493. eCollection 2023 Dec. Prev Med Rep. 2023. PMID: 38116254 Free PMC article.
-
Developing a single-session strategy for the implementation of take-home naloxone by community pharmacists using COM-B and design-thinking.Front Health Serv. 2023 Aug 1;3:1227360. doi: 10.3389/frhs.2023.1227360. eCollection 2023. Front Health Serv. 2023. PMID: 37600924 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical